Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00762632
NCT00762632CompletedPhase 1

An Open-label Phase I/II (Proof of Concept) Trial of an Combination of Nilotinib (AMN 107) and RAD001 in Patients With Acute Myeloid Leukemia

Technical University of Munich2 sites in 1 country40 target enrollmentStarted: December 1, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
40
Locations
2
Primary Endpoint
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to standard chemotherapy or not eligible to standard chemotherapy can be included. Patients will be treated with 400 mg Nilotinib bid (total daily dose 800 mg). RAD001 will be added after a treatment duration of 1 week in a dosage of 2,5 mg/day. Treatment duration will be 25 weeks.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with:
  • •De novo AML or secondary AML from MDS who are not candidates for myelosuppressive chemotherapy, or
  • •De novo AML or secondary AML from MDS who have relapsed disease or are refractory to standard therapy
  • •Patients at least 18 years or older
  • •Patients with WHO performance status of 0 to 2 with a life expectancy under treatment of at least 3 months
  • •Patients must have recovered from prior cytotoxic chemotherapy; treatment with Hydroxyurea or Ara-C is allowed until 24 hours to first administration of study drug.
  • •Patients must have a serum creatinine of <= 1.5 x ULN, SGOT/SGPT <= 3 x ULN and total bilirubin <= 2.0 x ULN
  • •Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • •Written informed consent obtained according to local guidelines

Exclusion Criteria

  • •Patients with AML FAB M
  • •Patients with an expected doubling of the peripheral blast within one week.
  • •Patients who had prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously.
  • •Impaired cardiac function, including any one of the following:
  • •LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by MUGA scan or echocardiogram
  • •Complete left bundle branch block
  • •Use of a cardiac pacemaker
  • •ST depression of > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
  • •Congenital long QT syndrome dose levels of 400 to 1200 mg QD. Many of the common adverse events reported in the imatinib Phase II leukemia (STI0106, STI0110) studies were also reported in the nilotinib Phase I study, although a notably lower frequency of peripheral edema was identified in the nilotinib study.
  • •History of or presence of significant ventricular or atrial tachyarrhythmias
  • •Clinically significant resting bradycardia (< 50 beats per minute)
  • •QTc > 450 msec on screening ECG (using the QTcF formula)
  • •QT prolonging concomitant medication
  • •Right bundle branch block plus left anterior hemiblock, bifascicular block
  • •Myocardial infarction within 12 months prior to starting Nilotinib
  • •Unstable angina diagnosed or treated during the past 12 months
  • •Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
  • •Female patients who are pregnant or breast feeding, or adults of childbearing age not employing an effective method of birth control.
  • •Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study.
  • •Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease
  • •Patients with uncontrolled active infection.
  • •Patient with any pulmonary infiltrate on the baseline chest X-ray known to be new in the previous 4 weeks. Prior treatment with any investigational drug within the preceding 4 weeks
  • •Chronic treatment with systemic steroids or another immunosuppressive agent
  • •Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
  • •Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
  • •Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
  • •A known history of HIV seropositivity
  • •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  • •Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
  • •Hypokalemia
  • •Women who are pregnant or breast feeding, or women able to conceive and unwilling to practice an highly effective method of birth control.
  • •Patients who have received prior treatment with an mTor inhibitor.
  • •History of noncompliance to medical regimens
  • •Patients unwilling to or unable to comply with the protocol

Outcomes

Primary Outcomes

To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study

Time Frame: four years

Secondary Outcomes

  • To determine the duration of hematological response. To evaluate overall survival. To evaluate the safety profile of a combination treatment of Nilotinib and RAD001. • To evaluate improvement of symptomatic parameters. • To assess mTor, cKit a(four years)

Investigators

Sponsor
Technical University of Munich
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19COVID19
NCT04551768Bausch Health Americas, Inc.51
Withdrawn
Phase 1
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2COVID19
NCT04356677Bausch Health Americas, Inc.
Unknown
Phase 2
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal CancerMetastatic Colorectal Cancer
NCT01249521Austin Health40
Completed
Phase 1
Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and YouthHIV Infections
NCT04301154Henry M. Jackson Foundation for the Advancement of Military Medicine25
Completed
Phase 1
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia
NCT01558167German CLL Study Group22